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1.0 INTRODUTION: 
Psoriasis is one of the most common human skin 
diseases. It occurs when the immune system mistakes the 
skin cells as a pathogen and sends out faulty signals that 
speed up the growth cycle of the skin. It leads to rapid 
accumulation of skin cells on the skin surface forming a 
thick silvery surface, dry red patches which may pain. 
This is a persistent and long-lasting disease affecting 1-3 
% of the world’s population1-3. About 80% of patients 
with psoriasis are treated topically. 4, 5  Although steroids 
may work very well at first, psoriasis may become 
resistant to them over time. Twice a day application of 
formulation belonging to corticosteroid category and 
vitamin D analogues is the most commonly used 
treatment for psoriasis. Formulation of vitamin D should 
be applied first to the skin, followed by corticosteroid 
formulation after determined duration. The greatest 
limitation to the combined monotherapy is the 
inconvenience of administration6. Topical corticosteroids 
are now often used in combination with topical vitamin 
D analogs. Topical pharmaceutical composition 
comprising a combination of vitamin D analogue and 
topical corticosteroid would likely result in better patient 
compliance. However, the drugs belonging to 
corticosteroids and vitamin D3 analogues are stable at 
different pH values, combination of the same is 
challenging to manufacture 7.Calcipotriol is sensitive to 
oxidizing agents and acidic residues; it reacts with 
alcohols, and  easily undergoes epimerisation processes. 
Contrary to this, corticosteroids like prednicarbate are 
stable under acidic conditions, but sensitive to alkaline 
residues and oxidizing agents. Due to differences in 
physico-chemical properties and stabilities it has not 
previously been possible to successfully combine the two 
drug substances in a single formulation. To explore the 
effect of simultaneous treatment and to improve patient 
compliance alleviating the inconvenience of separate 
applications, a combination formulation consisting 
Betamethasone dipropionate and Calcipotriol in a single 
vehicle achieving optimal delivery of both substances 
into the skin was successfully developed by Leo 
Pharma8. Furthermore, the excellent stability of these 
two drugs has also been documented 9.  A two-
compound ointment containing Calcipotriol and 
corticosteroid betamethasone dipropionate has been 
shown to be effective and safe in psoriasis in many of the 
clinical trials 13-15. The aim of the present study was to 
combine the two drug substances, Calcipotriol and 
Prednicarbate, in a single formulation, and to achieve a 
skin delivery similar to the marketed product Daivobet 
ointment which contains calcipotriol and betamethasone, 
50mcg and 0.5mg/g.  
2.0 MATERIALS: 
 Calcipotriol Monohydrate was supplied by D.K 
Pharmachem Pvt. Ltd. and Prednicarbate was provided 
by Sun Pharma. Propylene Glycol (PG), Butylated 
Hydroxy toluene (BHT), White Soft Paraffin, Cetyl 
Alcohol, Light Liquid paraffin, Butylated Hydroxy 
Anisole (BHA), Vitamin E Acetate were gift samples 
from Elder Pharmaceuticals Ltd, Navi Mumbai, India. 
Polyoxypropylene – 15-  Stearyl ether (ARLAMOL 
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PS15E LQ) was obtained from Croda Chemicals Pvt. 
Ltd, Mumbai. Propylene Glycol Dipelargonate (DPPG) 
was obtained from Gattefosse , Mumbai. 
3.0 METHODS  
3.1 PREPARATION OF FORMULATIONS 
Test formulation ointments were prepared by dissolving 
Calcipotriol in different solvents including 
Polyoxypropylene – 15- Stearyl ether, Propylene Glycol 
and Propylene Glycol Dipelargonate and then adding 
melted ointment base with antioxidant. Both phases were 
700C. Prednicarbate was suspended in liquid paraffin and 
added to the mixture. The ointments were continuously 
stirred to ensure that both the drug substances were 
homogenously distributed. The test formulations were 
based on the variation of concentrations of antioxidants 
and solvents; 5% Light Liquid Paraffin (oint. F1); 
Combination of BHA, BHT and disodium EDTA (oint 
F2),  10% Propylene glycol with 0.05%Vitamin E 
Acetate (oint. F3), 5% PSE and 0.050 % of Vitamin E 
Acetate (oint. F4); 10% PSE and 0.050 % of Vitamin E 
Acetate (oint. F5);  and 5% DPPG and 0.050% of 
Vitamin E Acetate (oint. F6), 10 % DPPG and 0.050% of 
Vitamin E Acetate (oint. F7). The amount of white soft 
paraffin was varied accordingly. All percentages are 
weight to weight-ratios (w/w). 
 
Table 1: Formulation details of Calcipotriol and Prednicarbate ointments 
Ingredients   Quantity (%w/w) 
 F1 F2 F3 F4 F5 F6 F7 
Calcipotriol * 0.005 0.005 0.005 0.005 0.005 0.005 0.005 
Prednicarbate 0.250 0.250 0.250 0.250 0.250 0.250 0.250 
Light Liquid Paraffin 5.000 5.000 5.000 3.000 3.000 3.000 3.000 
Cetyl Alcohol  6.000 6.000 6.000 -- -- -- -- 
White Soft Paraffin**  79.585 79.585 78.695 91.675 85.675 91.675 86.675 
Propylene Glycol -- 9.000 10.000 -- -- -- -- 
Butylated Hydroxytoluene -- 0.020 --- 0.020 0.020 0.020 0.020 
Butylated Hydroxyanisole -- 0.020 -- -- -- -- -- 
Disodium EDTA -- 0.120 -- -- -- -- -- 
Polyoxypropylene – 15-  
Stearyl ether (ARLAMOL 
PS15E LQ)  
-- -- -- 5.000 10.000 -- -- 
Propylene Glycol 
Dipelargonate (DPPG) 
-- -- -- -- -- 5.000 10.000 
Vitamin E Acetate -- -- 0.050 0.050 0.050 0.050 0.050 
* added as 52.18 mcg of Calcipotriol Monohydrate equivalent to 50 mcg of Calcipotriol. **Quantity to be adjusted to final 100% 
w/w based on the equivalency factor of Calcipotriol.  
 
3.2 PHYSICAL EVALUATION OF OINTMENTS 
3.2.1 Appearance:  
Appearance of ointment was evaluated by visually 
checking for clarity and texture. 
3.2.2 Spreadability:  
Spreadability is a term expressed to denote the extent of 
area to which the cream readily spreads on application to 
skin or affected part. The therapeutic efficacy of a 
formulation also depends on its spreading value. Hence 
determination of spreadability is very important in 
evaluating ointment characteristics. Assessment of the 
spreadability of the prepared formulations were 
determined individually by measuring the spreading 
diameter of 1g of ointment between two glass plates 
(20cm × 20cm) by having a standard weight of 125g on 
the upper plate10.  
3.2.3. pH:  
The pH of the prepared formulations were determined by 
using digital pH meter 
3.2.4. Centrifuge test: 
 It is a unique tool for the evaluation of accelerated 
deterioration of ointments. It was determined by using 
Remi centrifuge in 10 ml-graduated cylinder at 4000 rpm 
for 10 min11.  
3.2.5 Freeze-thaw cycle study:  
This test method is intended to determine the effects of 
freezing and thawing on the physical parameters of the 
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formulation. The ointments were packed in aluminum 
collapsible tubes and exposed to 10 freeze- thaw Cycles.  
The tubes were first exposed to freeze cycle at 2 -80 C for 
a period of 18 hours. After the freeze cycle, tubes were 
kept at room temperature for 6 hours. Then immediately 
begin the thaw cycle at a temperature of 40- 450 C for a 
period of 18 hours.  After the thaw cycle, tubes were kept 
at room temperature for 6 hours. 
One freeze-thaw cycle is defined as a complete freeze 
cycle followed by exposure at room temperature and 
complete thaw cycle followed by exposure at room 
temperature. The physical observation of ointment was 
recorded after every cycle.  
3.2.6 In-Vitro Skin Permeation Study: 
Skin from the back of pig ear has proved to have 
properties similar to those of human skin and has been 
suggested a good model for human skin 
permeability12.Hence, full-thickness skin was removed 
from the back of pig ears obtained from a local abattoir. 
The subcutaneous tissues were removed carefully and 
skin was excised cut into appropriate pieces. The skin 
samples were mounted in open two-chamber Franz 
diffusion cell with a recipient volume of 10 ml. The 
diffusion cells were placed in a thermostated water bath 
maintaining a temperature of 320C on the skin surface. A 
mixture of 0.04 M isotonic phosphate buffer pH 7.4 and 
2-propanol (70:30) was used as recipient phase. After a 2 
hour equilibrium period, the test formulation was applied 
to the stratum corneum side of the skin and spread with a 
tared glass spatula. At appropriate time intervals an exact 
amount of the recipient phase was withdrawn and 
replaced by thermostated fluid. The permeation was 
followed for 24 hours and it was ensured that sink 
conditions were present. The samples were analyzed by 
HPLC method.  
3.2.7 HPLC Analysis of the Drug Substances: 
A reverse phase high-performance liquid 
chromatographic (RP-HPLC) method was developed for 
the analysis of calcipotriol and prednicarbate. The 
concentrations were quantified by simultaneous 
estimation method using a Waters Alliance 2996 HPLC 
system with Programmable Auto sampler. The 
substances were separated on a Kromosil C18, (250 x 
4.6mm) 5µ Isocratic illusion method using a  detector 
wave length of 264 nm, injection volume of 50 µl and a 
flow rate of 1.0 ml/min. The mobile phase consisted of 
Water and Methanol (150:850 v/v). The retention time 
was around 5 minutes for prednicarbate and 7.5 minutes 
for calcipotriol.  
3.2.8 In-vivo screening of Antipsoriatic potential using 
oxazolone induced contact dermatitis   model: 
17
 
In-vivo screening of Antipsoriatic potential was carried 
out using female BALB/c mice (20-25g). The 
effectiveness of the formulation was studied using 
oxazolone-induced contact dermatitis animal model.  
Female BALB/c mice were sensitized by the application 
of Oxazolone to the abdomen then ears were 
rechallenged with 20µl of 1% oxazolone in a mixture of 
acetone and olive oil (4:1) every 3rd day for two weeks 
to induce severe dermatitis. Treatment was conducted 
with topical application of formulation F4 once a day to 
both sides of the ears. Results were compared with the 
reference. Group without any disease induction served as 
placebo control while the group with disease induction 
but no treatment served as positive control for the study. 
Antipsoriatic activity was evaluated in terms of 
suppression in the ear thickness which was measured 
using vernier calipers.  
3.2.9 Microbial Evaluation:
 18, 19
 
3.2.9.1 Total aerobic bacterial count:  
The test was performed by pour plate method on the 
optimized promising formulation F4.10g ointment was 
added to previously sterilized 90ml of buffered sodium 
chloride-peptone solution pH 7.0. Pipette 1.0ml of above 
dilution into two sets (duplicate). Add 15 – 20 ml of 
sterile Casein soya bean digest agar which has been 
previously melted and cooled at 450C to two petri dishes 
in one set for bacterial count. 
3.2.9.2 Total Yeast and Moulds count: 
Add 15-20 ml of sterile Sabouraud’s  Chloramphenicol 
agar which has been previously melted and cooled at 
450C to two petri dishes in another set for fungal (yeast 
and mould) count. Incubate the plates for bacterial count 
at 30 – 350C for fungal count at 20-250C for 5 days with 
negative control. After incubation, observe the plates and 
count the number of colonies formed.  
3.2.9.3 Test for pathogens:  
Test was performed to confirm the absence of pathogens 
i.e. Escherichia coli, staphylococcus aureus, 
Pseudomonas aeruginosa and Salmonella spp.  in the 
ointment using the relevant medias. 
Escherichia Coli: Take 10 g of ointment and add 90ml 
of buffered Sodium Chloride –peptone solution pH7.0 
and use 10ml to inoculate 100ml of Casein Soyabean 
Digest Broth and incubate at 35- 370C for 18-48 hours. 
Shake the container, transfer 1 ml to 100 ml of 
MacConkey broth and incubate at 43-450C for 18-24 h. 
Subculture on plates of Mac Conkey agar at 35- 370C for 
18-72 hours. 
Staphylococcus aureus: Add 10 g of ointment to 90 ml 
of buffered sodium chloride peptone solution pH7.0 and 
use 10ml or the quantity corresponding to 1 g to 
inoculate 100ml of Casein Soya bean digest  broth and 
incubate at 35- 370C for 18-48 hrs. Subculture on a plate 
of Baird –Parker agar and incubate at 35- 370C for 18-72 
hrs 
Pseudomanas aeruginosa: Add 10 g of ointment to 90 
ml of buffered sodium chloride peptone solution pH7.0 
and use 10ml or the quantity corresponding to 1 g to 
inoculate 100ml of Casein Soya bean digest  broth and 
incubate at 35- 370C for 18-48 hrs. Subculture on a plate 
of Cetrimide Agar and incubate at 35- 370C for 18-72 hrs 
Salmonella Spp.: Add 10 g of ointment to 90ml of 
Casein Soya bean digest broth and incubate 35- 370C for 
18-24 hrs. Transfer 1 ml of the enrichment culture to 
10ml of Tetrathionate bile brilliant green broth and 
incubate at 41- 430C for 18-24 hrs. Subculture on  
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Deoxycholate Citrate Agar and Xylose lycin 
Deoxycholate agar.- Incubate at 35 -37 for 18 -72 
hrs.The probable presence of salmonella is indicated by 
the growth of culture having the following appearance. 
Deoxycholate Citrate Agar: Well developed, colourless 
colonies. 
Xylose lycin Deoxycholate agar: Well developed red 
coloured colonies with or without black centres 
4.0 RESULT AND DISCUSSION: 
4.1 Physical evaluation of ointments: 
Discussion: 
Appearance of all formulated ointments was evaluated 
by visually checking for clarity and texture. White, 
translucent, homogenous, odourless ointments were 
obtained. 
Formulations complied with the physical evaluation 
parameters like pH, physical stability, centrifugation, 
spreadability were found to be acceptable as notified in 
table 2.  
 
Table 2: Physical parameters observation 
Formulation F1 F2 F3 F4 F5 F6 F7 
Spreadability (mm) 62 65 60 65 63 64 60 
pH 5.21 5.37 5.0 5.43 5.51 5.62 5.66 
Centrifuge test No Phase 
Separation 
No Phase 
Separation 
No Phase 
Separation 
No Phase 
Separation 
No Phase 
Separation 
No Phase 
Separation 
No Phase 
Separation 
 
4.2 Freeze-thaw cycle stability study:  
All the formulations (F1 to F7) were exposed to freeze thaw stability and the physical observations after 10 th cycle are 
recorded in Table 3. 
 
Table 3: Physical parameters observation after 10 freeze-thaw cycles 
Formulation F1 F2 F3 F4 F5 F6 F7 
pH 5.77 6.22 6.18 5.98 6.03 6.08 6.14 
Centrifuge Test Ointment 
turned 
yellowish 
No Phase 
Separation 
Ointment 
turned 
slightly 
yellowish 
No Phase 
Separation 
No Phase 
Separation 
No Phase 
Separation 
No Phase 
Separation 
 
 
4.3 In-Vitro Skin Permeation Studies: 
The chemical analysis of formulations F1 and F3 was not 
performed as these batches showed significant changes 
in physical parameters during freeze-thaw Stability 
Discussion  
The in vitro skin permeation profiles of prednicarbate 
and calcipotriol in the different test formulations are 
shown in Fig. 1A and 1B. It is seen that the rate of drug 
release for both drug substances was found to be related 
to the solvent systems used in the formulations. 
Propylene Glycol (oint. F2) was found to have no 
enhancing effect itself on either of the drug substances 
compared with the reference product (Daivobet). 
Polyoxypropylene – 15-  Stearyl Ether  (PSE) used in the 
concentration of 5 % (oint. F4) and 10 % (oint F5) had a 
marked effect on the cumulated permeated amount of 
both drug substances whereas formulations containing 
Propylene Glycol Dipelargonate (DPPG) used in the 
concentration of 5 % (oint. F6) and 10 % (oint F7) had 
no significant effect on the rate and extent of permeation. 
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Figure 1: In vitro skin permeation profiles of Prednicarbate (A), and Calcipotriol (B) from the test formulations based 
on different vehicle components 
 
4.4 HPLC Analysis of the Drug Substances: 
Discussion:  
The drug content of calcipotriol and Prednicarbate in the 
ointment formulations F-4 to F-7 were well within the 
limits whereas the Calcipotriol content of Formulation 
F2 was found on lower side. This could be due to the 
oxidation of Calcipotriol as there was no antioxidant 
used in the formulation F2.  
 
Table 4: Percentage drug contents of Calcipotriol and Prednicarbate in the ointment formulations 
Formulation 
drug content (%w/w) 
F2 F4 F5 F6 F7 
Calcipotriol 89.54 98.6 99.67 98.41 99.05 
Prednicarbate 101.3 99.64 100.10 100.07 98.93 
 
 
Figure 2: HPLC assay chromatogram showing the peaks of Calcipotriol and Prednicarbate. 
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4.5 In-vivo screening of Antipsoriatic potential using 
oxazolone induced contact dermatitis   model: 
Discussion: 
Ear thickness is an index of skin inflammation and was 
measured using a vernier caliper. In vivo efficacy is 
dependent on the rate at which the drug penetrates the 
skin and becomes available at the site of action. To 
verify this, therapeutic efficacy of optimized formulation 
was evaluated. Reduction in inflammation for group 
treated with optimized Formulation F4 as well as 
reference (Diavobet) was significantly higher as 
compared with the placebo and no-treatment group as 
shown in figure 3.  
 
 
Figure 3: Effect of Calcipotriol and Prednicarbate ointment formulation F4 on the thickness of mouse ear induced by 
repeated application of Oxazolone. 
 
4.5 Microbial Evaluation: 
4.5.1 Total aerobic bacterial count:  
Discussion: 
The total aerobic microbial count (TAMC) is considered 
to be equal to the number of colony-forming units (cfu) 
found using casein- soya bean digest agar. The total 
yeast and mould count (TYMC) is considered to be equal 
to the number of cfu found using Sabouraud 
Chloramphenicol agar. The total viable aerobic count is 
the sum of the bacterial count and yeast and mould 
count.  
Less than 10 cfu/g bacterial count was observed in 
optimized formulation F4 after 5 days of incubation. 
4.5.2 Test for pathogens:  
Discussion: 
Growth rate of red, non-mucoid colonies of gram-
negative rods indicate the possible presence of E-coli. 
The product passes if such colonies are not seen or if the 
confirmatory biochemical tests are negative.  
Black colonies of gram – positive cocci surrounded by a 
clear zone indicate the presence of S. aureus. 
Confirmation may be effected by suitable biochemical 
tests such as the coagulase test and the 
deoxyribonuclease test. The product passes the test if 
colonies of the type described do not appear on Baird-
Parker agar or if the confirmatory biochemical tests are 
negative. 
If no growth of micro organism is detected, the product 
passes the test. If growth of gram negative rod occurs 
then they Casein Soya bean digest broth and incubate at 
41- 430C for 18-24 hrs. The product passes the test if no 
growth occurs at 41- 430C 
The presence of salmonellae is previously confirmed if 
the deep inoculation but not the surface culture there is a 
change of colour from red to yellow and usually 
formation of gas with or without production of hydrogen 
sulfide in the agar. The product passes the test if colonies 
of the type do not appear. 
No pathogens were detected in the optimized formulation 
F4. 
5.0 CONCLUSION:  
After taking trials with different anti-oxidants and 
solvents at different concentration levels, it was observed 
that the product with 5 % Polyoxypropylene – 15- 
Stearyl ether (PSE) and 0.050% of Vitamin E acetate  
resulted in antipsoriatic potential comparable to the 
marketed product.   
PSE is used as an emollient in cosmetic products and 
also as a drug solvent in pharmaceuticals. It was found to 
be a very effective solvent for both drug permeability. 
PSE is lipophilic in nature hence, when a high 
concentration is used in the vehicle; the skin vehicle 
partition coefficient is expected to decrease leading to 
decrease in the drug permeability. The results 
demonstrated that the type and the concentration of the 
solvent had a significant influence on the skin 
permeability. Formulations based on DPPG had no 
overall effect on skin permeability whereas the solvent 
PSE had a marked influence. The study proved it is 
possible to develop a formulation which combined 
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calcipotriol and prednicarbate in a single vehicle 
achieving optimal delivery of both substances into the 
skin.  
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